Through the Allergist’s Lens: Achieving Optimal Outcomes in Patients with Mild-to-Moderate Atopic Dermatitis

Release date: June 7, 2019
Expiration date: June 7, 2020
Estimated time to complete activity: 1.25 hour(s)



Mark Boguniewicz, MD
Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Health
University of Colorado School of Medicine
Denver, Colorado

Peck Ong, MD
Associate Professor of Clinical Pediatrics
Keck School of Medicine
University of South California
Children’s Hospital Los Angeles
Los Angeles, California

Myron J. Zitt, MD
Associate Professor of Clinical Medicine
Department of Medicine
State University of New York
Stony Brook, New York
Director Adult Allergy Clinic
Nassau University Medical Center
East Meadow, New York


Numerous factors contribute to suboptimal outcomes in the treatment of patients with atopic dermatitis (AD), including uncertainty among healthcare providers about optimal strategies for diagnosis and assessment of severity, and management approaches that are inconsistent with current evidence-based recommendations and guidelines. The following program is designed to address these issues by educating clinicians about overall strategies that have been demonstrated to improve outcomes in patients with AD, particularly those with mild to moderate disease. The activity includes information on how to make safe and efficacious choices among established and emerging pharmacotherapies based on up-to-date clinical data and provides guidance on how to facilitate treatment adherence and improve outcomes through improved communication strategies.


This program is intended for allergists, immunologists, nurse practitioners, physician assistants, and any healthcare professionals involved in the management and treatment of patients with AD.


Upon completion of this activity, participants should be better able to:

  • Recognize the most recent clinical practice guidelines and recommendations for AD
  • Evaluate strategies to facilitate accurate diagnosis and severity assessment in patients with AD
  • Translate the safety and efficacy data of established and emerging therapies into patient-focused treatment plans for patients with mild to moderate AD
  • Analyze the benefit of AD action plans, improved communication, and SDM to improve treatment adherence in patients with AD

There are no fees for participating and receiving CME credit for this activity. During the period of June 7, 2019 through June 7, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education designates this enduring material for a maximum of 1.25 AMA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Mark Boguniewicz, MD
Consultant: Lilly, Pfizer, Regeneron, Sanofi
Speakers’ Bureaus: Regeneron, Sanofi
Research: Regeneron

Peck Ong, MD
Consultant: Pfizer
Research: Incyte, Regeneron

Myron J. Zitt, MD
Consultant: AstraZeneca, Novartis, Pfizer

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.


This CME activity is provided by Integrity Continuing Education.


This activity is supported by an independent education grant from Pfizer.


Continue to Pretest